Cargando…
Biologics for Reducing Cardiovascular Risk in Psoriasis Patients
Psoriasis is a chronic inflammatory skin disease with a high prevalence of cardiovascular disease (CVD), obesity, dyslipidemia, hypertension, diabetes mellitus, and metabolic syndrome. Among them, CVD is the most common cause of morbidity and mortality in psoriasis patients. Since CVD is associated...
Autores principales: | Terui, Hitoshi, Asano, Yoshihide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918118/ https://www.ncbi.nlm.nih.gov/pubmed/36769825 http://dx.doi.org/10.3390/jcm12031162 |
Ejemplares similares
-
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
por: Sekine, Mana, et al.
Publicado: (2023) -
Psoriasis and Cardiovascular Risk: A Comprehensive Review
por: Masson, Walter, et al.
Publicado: (2020) -
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2022) -
The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors
por: Amagai, Ryo, et al.
Publicado: (2023) -
Novel anti‐inflammatory therapies to reduce cardiovascular burden of psoriasis
por: Piros, Éva Anna, et al.
Publicado: (2021)